394
Views
11
CrossRef citations to date
0
Altmetric
Original Articles

Identification and validation of a prognostic 8-gene signature for acute myeloid leukemia

&
Pages 1981-1988 | Received 29 Sep 2019, Accepted 08 Mar 2020, Published online: 08 Apr 2020
 

Abstract

In the present study, we aimed to identify some genes closely related to AML prognosis and investigate their potential roles. RNA-seq data of AML samples were accessed from the TCGA database and then analyzed in the Wilcox test. AML survival-related genes were selected and an 8-gene signature-based risk score model was in turn constructed (including TET3, S100A4, BATF, CLEC11A, PTP4A3, SPATS2L, SDHA, and ATOX1 8 feature genes) using the multivariate Cox regression analysis. Kaplan–Meier analysis was performed on the 8 genes in the training set (p = 2.826e − 11) and the test set (p = 2.213e − 2), and there was a remarkable difference in survival between the high and low-risk samples. Meanwhile, ROC analysis was conducted and revealed the relative higher accuracy of the risk score model applied in both the training set (1-year AUC = 0.864; 3-year AUC = 0.85) and test set (1-year AUC = 0.685; 3-year AUC = 0.678). Our study helps to extend our knowledge of the potential methods for AML prognosis.

    Highlights

  1. A prognostic 8-gene (including TET3, CLEC11A, ATOX1, S100A4, BATF, PTP4A3, SPATS2L and SDHA 8) signature for acute myeloid leukemia (AML) was identified and validated.

  2. The influence of the expression of single gene in the model on the survival risk of AML patients was confirmed and the risk rate of 8 single-gene was compared.

Author contributions

Dr. YL Zhang and LY Xiao contributed to the study design. YL Zhang conducted the literature search. YL Zhang and LY Xiao acquired the data. YL Zhang and LY Xiao wrote the article. YL Zhang revised the article and gave the final approval of the version to be submitted. All authors read and approved the final manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability

The data used to support the findings of this study are available from the corresponding author upon request.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.